After 72 weeks, patients who received up to 6 mg of orforglipron averaged a weight loss of 5.5%, those who received 12 mg averaged 7.8%, and those who received 36 mg averaged 10.5%, while the placebo group averaged just 2.2%
The most common include nausea, vomiting, diarrhea, and mild abdominal discomfort
Dinh Tran, MD at Family Healthcare Shoreline for Oral GLP-1 Weight Loss
So far, studies have reported: Phase 2 (48 weeks): up to 24.2% average weight loss Phase 3 TRIUMPH-4 topline (68 weeks): 28.7% average weight loss (press release) What that looks like: If you start at 100 kg : 24.2% 24 kg average loss 28.7% 29 kg average loss Side effects and safety signals (what we know so far) Phase 2 (peer-reviewed) In the phase 2 trial, the most common adverse events were gastrointestinal and dose-related, typically mild to moderate
Why Choose Trifecta for GLP-1 Diet
2023, doi: 10.1016/j.phrs.2023.106960